NOVAST Laboratories, Limited (SHE:301569)

NOVAST Laboratories Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,329	1,099	863.13	638.07	475.57	190.03
Trading Asset Securities	80.85	100.19	146.18	170.4	228.09	15.03
Cash & Short-Term Investments	1,410	1,199	1,009	808.46	703.67	205.06
Cash Growth	-	18.81%	24.84%	14.89%	243.16%	3.30%
Accounts Receivable	193.37	173.02	132.06	113	80	154.76
Other Receivables	2.9	2.35	2.46	1.64	0.01	220.28
Receivables	196.27	175.37	134.51	114.64	80	375.04
Inventory	220.51	214.55	227.95	262.05	262.55	188.87
Other Current Assets	35.81	29.65	33.95	40.15	50.79	39.11
Total Current Assets	1,863	1,619	1,406	1,225	1,097	808.07
Property, Plant & Equipment	589.45	594.01	567.45	444.66	345.29	336.52
Other Intangible Assets	42.99	43.17	44.04	44.9	45.75	18.4
Long-Term Deferred Tax Assets	30.05	29.45	28.79	29.87	25.97	19.88
Long-Term Deferred Charges	-	-	-	-	-	2.63
Other Long-Term Assets	7.71	8.48	6.51	6.99	13.88	6.49
Total Assets	2,533	2,294	2,053	1,752	1,528	1,192

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	9.54	13.02	8.93	9.18	3.09	2.62
Accrued Expenses	21.04	42.29	44.8	37.29	24.92	25.65
Current Income Taxes Payable	27.07	21.47	12.75	16.26	10.43	9.03
Current Unearned Revenue	9.06	11.9	5.08	3.36	3.48	2.33
Other Current Liabilities	72.53	77.96	91.19	45.87	41.65	177.22
Total Current Liabilities	139.24	166.64	162.75	111.96	83.57	216.86
Long-Term Unearned Revenue	2.57	117.21	98.6	113.93	2.91	7.48
Other Long-Term Liabilities	110.11	-	-	-	114.44	77.96
Total Liabilities	251.93	283.86	261.35	225.9	200.91	302.31

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	757.86	757.86	757.86	757.86	757.86	668.53
Additional Paid-In Capital	863.45	817.81	758.31	753.39	670.44	341.94
Retained Earnings	661.16	434.75	274.93	14.78	-101.01	-120.44
Comprehensive Income & Other	-1.34	-0.42	0.07	-0.22	-0.3	-0.35
Shareholders' Equity	2,281	2,010	1,791	1,526	1,327	889.69
Total Liabilities & Equity	2,533	2,294	2,053	1,752	1,528	1,192

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Cash (Debt)	1,410	1,199	1,009	808.46	703.67	205.06
Net Cash Growth	-	18.81%	24.84%	14.89%	243.16%	3.30%
Net Cash Per Share	1.86	1.58	1.33	1.07	0.93	0.34
Filing Date Shares Outstanding	-	757.86	757.86	757.86	753.35	668.53
Total Common Shares Outstanding	-	757.86	757.86	757.86	753.35	668.53
Working Capital	1,724	1,452	1,243	1,113	1,013	591.21
Book Value Per Share	-	2.65	2.36	2.01	1.76	1.33
Tangible Book Value	2,238	1,967	1,747	1,481	1,281	871.29
Tangible Book Value Per Share	-	2.60	2.31	1.95	1.70	1.30
Buildings	-	174.51	137.74	136.44	137.61	137.61
Machinery	-	516.25	478.03	461.97	424.64	403.75
Construction In Progress	-	246.83	261.65	124.6	30.4	11.37

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 30, 2026

Data Sources Report a data error